Liporyx is developing a bioinspired lipid-like polymer technology to safely and specifically deliver nucleic acid therapeutics to diverse cell types in the body. Most RNA therapeutics do not traverse the body well and are typically removed from circulation by the liver, limiting their effectiveness for many diseases. A highly versatile drug delivery system lies at the heart of Liporyx, enabling the precise delivery of therapeutic payloads directly into the cytosol of targeted cells. We are using modular approach to engineer this platform, with the aim of unlocking the vast array of therapeutic targets which are currently undruggable using existing formulations.
This research project will allow for the further demonstration of the platform technology’s benefits in preclinical models, validation with therapeutic RNA targeting immune checkpoint receptors for cancer immunotherapy, and for pitching to potential investors. We are on a mission to drive forward RNA therapeutics, unlocking their potential to transform the pharmaceutical industry landscape and enhance the lives of millions of patients worldwide.
